- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Intellia Therapeutics Inc (NTLA)
Intellia Therapeutics Inc stock price live, this page displays NASDAQ NTLA stock exchange data. View the NTLA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Intellia Therapeutics Inc real time stock price chart below.
What Is the Intellia Therapeutics Inc Stock Price Today?
The Intellia Therapeutics Inc stock price today is 14.64.
What Is the Stock Symbol for Intellia Therapeutics Inc?
The stock ticker symbol for Intellia Therapeutics Inc is NTLA.
Is NTLA the Same as $NTLA?
$NTLA is a common way to refer to the Intellia Therapeutics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Intellia Therapeutics Inc Trade On?
Intellia Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Intellia Therapeutics Inc a Good Stock to Buy?
Determining whether Intellia Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Intellia Therapeutics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NTLA quote. (ISIN: US45826J1051)
What Is the Intellia Therapeutics Inc Stock Price Today?
The Intellia Therapeutics Inc stock price today is 14.64.
What Is the Stock Symbol for Intellia Therapeutics Inc?
The stock ticker symbol for Intellia Therapeutics Inc is NTLA.
Is NTLA the Same as $NTLA?
$NTLA is a common way to refer to the Intellia Therapeutics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Intellia Therapeutics Inc Trade On?
Intellia Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Intellia Therapeutics Inc a Good Stock to Buy?
Determining whether Intellia Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Intellia Therapeutics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NTLA quote. (ISIN: US45826J1051)
Currency in USD
14.64
-0.14(-0.98%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.46
15.28
52 wk Range
6.73
28.25
Earnings results expected in 15 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.4615.28
52 wk Range
6.7328.25
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NTLA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
25.29
Upside
+72.72%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
5 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Intellia Therapeutics Inc SWOT Analysis
Market Potential | Analyst targets range from $26 to $65, reflecting optimism about Intellia's potential to capture significant market share in multi-billion dollar genetic disease markets |
Navigating Challenges | Explore how Intellia addresses safety concerns and regulatory hurdles while pursuing its goal of revolutionizing genetic disease treatment through one-time therapies |
Financial Fortitude | With $707.1M in cash, Intellia is well-positioned to fund operations into 2027/2028, balancing ambitious clinical programs with prudent financial management |
Gene Editing Pionee | Intellia Therapeutics leads CRISPR/Cas9 innovation, advancing transformative therapies for genetic diseases with promising clinical trial progress in HAE and ATTR amyloidosis |
Intellia Therapeutics Inc Earnings Call Summary for Q4/2025
- Q4 2025 EPS of -$0.83 beat forecast of -$0.96; revenue hit $23.02M vs. $12.08M expected, marking 90.56% surprise driven by collaborations.
- R&D expenses dropped 24.1% YoY to $88.7M; net loss improved 25.6% to $95.8M as company optimizes costs ahead of lonvo-z commercial launch in 2027.
- Cash position stands at $605.1M as of Dec 31, 2025, projected to fund operations into second half of 2027 amid restructuring efforts.
- Stock rose 4.17% in pre-market trading; FY2026 EPS guidance ranges from -$0.95 to -$1.01 with continued revenue growth anticipated.
Last Updated: 02/26/2026, 09:20 AM
Read Full TranscriptCompare NTLA to Peers and Sector
Metrics to compare | NTLA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNTLAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.2x | −3.4x | −0.5x | |
PEG Ratio | −0.15 | 0.11 | 0.00 | |
Price / Book | 2.6x | 14.1x | 2.6x | |
Price / LTM Sales | 25.4x | 99.1x | 3.2x | |
Upside (Analyst Target) | 31.2% | 366.9% | 47.6% | |
Fair Value Upside | Unlock | 3.6% | 6.1% | Unlock |
Analyst Ratings
14 Buy
9 Hold
2 Sell
Ratings:
25 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 25.29
(+72.72% Upside)
Earnings
Latest Release
Feb 26, 2026
EPS / Forecast
-0.83 / -0.96
Revenue / Forecast
23.02M / 12.08M
People Also Watch
FAQ
What Is the Intellia Therapeutics Inc (NTLA) Stock Price Today?
The Intellia Therapeutics Inc stock price today is 14.64 USD.
What Stock Exchange Does Intellia Therapeutics Inc Trade On?
Intellia Therapeutics Inc is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Intellia Therapeutics Inc?
The stock symbol for Intellia Therapeutics Inc is "NTLA."
What Is the Intellia Therapeutics Inc Market Cap?
As of today, Intellia Therapeutics Inc market cap is 1.72B USD.
What Is Intellia Therapeutics Inc's Earnings Per Share (TTM)?
The Intellia Therapeutics Inc EPS (TTM) is -3.81.
When Is the Next Intellia Therapeutics Inc Earnings Date?
Intellia Therapeutics Inc will release its next earnings report on Apr 30, 2026.
From a Technical Analysis Perspective, Is NTLA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Intellia Therapeutics Inc Stock Split?
Intellia Therapeutics Inc has split 0 times.
How Many Employees Does Intellia Therapeutics Inc Have?
Intellia Therapeutics Inc has 377 employees.
What is the current trading status of Intellia Therapeutics Inc (NTLA)?
As of Apr 15, 2026, Intellia Therapeutics Inc (NTLA) is trading at a price of 14.64 USD, with a previous close of 14.78 USD. The stock has fluctuated within a day range of 14.46 USD to 15.28 USD, while its 52-week range spans from 6.73 USD to 28.25 USD.
What Is Intellia Therapeutics Inc (NTLA) Price Target According to Analysts?
The average 12-month price target for Intellia Therapeutics Inc is 25.29 USD, with a high estimate of 106 USD and a low estimate of 5 USD. 14 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Buy. The stock has an +72.72% Upside potential.
What Is the NTLA Premarket Price?
NTLA's last pre-market stock price is 14.85 USD. The pre-market share volume is 23,450.00, and the stock has decreased by 0.07, or 0.47%.
What Is the NTLA After Hours Price?
NTLA's last after hours stock price is 14.70 USD, the stock has decreased by -0.08, or -0.54%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.